What MT-2 is: a cyclic analog of alpha-MSH
The endogenous melanocortin agonist alpha-MSH is a 13-residue linear peptide derived from proopiomelanocortin (POMC). Its core message sequence, His-Phe-Arg-Trp, is the minimal pharmacophore recognized by melanocortin receptors. Alpha-MSH is potent but short-lived: as a flexible linear peptide it is rapidly degraded by peptidases and samples many conformations, most of which are not the receptor-bound one. Medicinal-chemistry programs in the late 1980s set out to build a more metabolically stable, conformationally constrained analog around that message sequence.
Melanotan II is the product of that effort. It replaces the flexible linear backbone with a lactam-bridged macrocycle that pre-organizes the His-D-Phe-Arg-Trp pharmacophore into a receptor-competent turn, and it substitutes the native L-Phe with D-Phe to resist enzymatic cleavage and bias the conformation. The result is a compact, protease-resistant peptide that retains high affinity across the melanocortin receptor family. In research settings MT-2 is therefore treated as a stabilized surrogate for alpha-MSH signaling rather than as a novel pharmacology of its own.
- Parent ligand: alpha-MSH, a POMC-derived 13-residue melanocortin agonist.
- Conserved pharmacophore: the His-Phe-Arg-Trp message sequence.
- MT-2 design goals: conformational constraint plus metabolic stability.
- Studied as a stabilized tool-compound surrogate for melanocortin signaling.
Molecular structure and the cyclic constraint
Melanotan II is a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. An N-terminal acetyl group and a C-terminal amide cap both termini, removing the charged ends that peptidases and the flexible linear form would otherwise present. The macrocycle is closed by a lactam bridge between the side-chain carboxyl of Asp and the side-chain amine of Lys, and the norleucine (Nle) residue substitutes for the oxidation-prone methionine of the native sequence.
This lactam bridge is the structural heart of the Melanotan II mechanism. By covalently tethering positions on either side of the message sequence, it locks His-D-Phe-Arg-Trp into a beta-turn geometry that closely matches the conformation the melanocortin receptors recognize. Pre-paying this conformational entropy cost at synthesis, rather than at the moment of binding, is what gives MT-2 its high affinity and its broad, non-selective activity across the receptor subtypes. The molecular reference values below are the published identifiers used to confirm identity on a certificate of analysis.
- N-acetylation and C-terminal amidation cap both termini.
- Asp-to-Lys side-chain lactam bridge forms the macrocycle.
- Nle replaces oxidation-prone Met to improve stability.
- The cyclic constraint pre-organizes the His-D-Phe-Arg-Trp turn.
The melanocortin receptor family: five GPCR subtypes
The melanocortin system comprises five class-A G-protein-coupled receptors, MC1R through MC5R, each canonically coupled to the stimulatory G-protein Gs. Agonist binding activates adenylyl cyclase, raises intracellular cyclic AMP (cAMP), and engages protein kinase A and, in pigment cells, the downstream transcription factor MITF. The subtypes differ in tissue distribution and physiology: MC1R sits on melanocytes and immune cells; MC2R (the ACTH receptor) is adrenal and, notably, is not activated by MT-2; MC3R and MC4R are predominantly central nervous system receptors involved in energy homeostasis; and MC5R is associated with exocrine tissue.
The system is unusual in being regulated by endogenous inverse agonists and antagonists, the agouti and agouti-related peptides (ASIP and AgRP), which oppose melanocortin agonism at specific subtypes. Because MT-2 engages several receptors at once, the literature uses it primarily to interrogate melanocortin signaling in general and, with subtype-selective tools as comparators, to dissect which physiological readout maps to which receptor. It is a broad agonist probe, not a subtype-selective one.
- MC1R: melanocytes and immune cells; pigment-cell signaling.
- MC2R: adrenal ACTH receptor; not activated by MT-2.
- MC3R and MC4R: central receptors in energy-balance research.
- MC5R: exocrine-tissue-associated; least characterized.
- All five signal principally through Gs to raise intracellular cAMP.
Non-selective agonism: the MT-2 binding profile
The defining pharmacological feature of Melanotan II is that it is a non-selective, high-affinity agonist across MC1R, MC3R, MC4R, and MC5R. Radioligand-binding and functional cAMP assays in receptor-transfected cell lines report nanomolar-range affinities at these subtypes, generally with greater potency and far longer duration of action than native alpha-MSH, which is the practical consequence of the cyclic, protease-resistant design. Unlike the native hormone, MT-2 does not meaningfully engage MC2R, the adrenal ACTH receptor, because MC2R has distinct ligand requirements.
In experimental use this broad profile is both the strength and the limitation of MT-2. As a tool it is valuable for switching on melanocortin signaling robustly and durably across a cell system, which is why it appears frequently as a positive-control agonist. But because it activates four subtypes simultaneously, a phenotype observed after MT-2 exposure cannot be attributed to a single receptor without additional selective agonists, selective antagonists (such as SHU9119 or the AgRP fragment), or receptor-knockout comparisons. Careful literature designs therefore pair MT-2 with these orthogonal tools.
- High-affinity agonist at MC1R, MC3R, MC4R, and MC5R.
- Minimal activity at MC2R (the ACTH receptor).
- Greater potency and longer action than alpha-MSH in vitro.
- Broad activity requires selective comparators to assign receptor-specific effects.
MC1R and melanogenesis pathways in cell models
The most extensively modeled arm of the Melanotan II mechanism is MC1R signaling in pigment cells. In cultured melanocytes and melanoma cell lines, MC1R agonism raises cAMP, activates PKA, and increases expression and activity of MITF, the master regulator of the pigmentation program. MITF in turn drives transcription of tyrosinase and the related enzymes TYRP1 and DCT that catalyze the conversion of tyrosine into melanin, and the literature reads out these steps as changes in enzyme expression, catalytic activity, and melanin content of the cultured cells.
This cell-model work is used to study the biochemistry of the melanogenesis pathway itself: the coupling between receptor occupancy and cAMP, the kinetics of MITF induction, the balance between eumelanin and pheomelanin synthesis, and how MC1R variants alter signaling output. MT-2 serves as a strong, stable agonist input for these in-vitro pathway studies. This is strictly molecular and cell-biology research into a signaling cascade; it is not a description of any cosmetic outcome, and no such use is described or endorsed here.
- MC1R to cAMP to PKA to MITF is the core signaling axis.
- MITF induces tyrosinase, TYRP1, and DCT expression.
- Readouts: enzyme activity, transcript levels, cellular melanin content.
- Used to probe MC1R-variant signaling and pathway kinetics in vitro.
MC4R and MC3R in appetite and energy-balance research
The central melanocortin receptors MC4R and MC3R are the focus of a large preclinical literature on energy homeostasis. MC4R in particular is a well-established node in the hypothalamic circuitry that integrates signals of energy status; loss-of-function MC4R mutations are among the most common monogenic contributors to severe early-onset obesity in humans, which has made the receptor a major target in metabolic pharmacology. Because MT-2 is a potent MC4R agonist, it is used in animal and cell models as an agonist probe to interrogate the downstream consequences of activating this pathway.
In these research designs MT-2 is a mechanistic tool for mapping melanocortin control of feeding and energy expenditure circuits, typically alongside selective MC4R agonists and antagonists to separate MC4R- from MC3R-mediated effects. The scientific interest is in the receptor biology and neurocircuitry, and this work informs the development of subtype-selective drug candidates. Nothing in this section constitutes a human protocol, dosing guidance, or a therapeutic or weight-related claim; MT-2 is referenced only as a laboratory agonist used to study receptor function.
- MC4R is a central regulator of energy balance and a validated metabolic target.
- MT-2 is used preclinically as an MC4R/MC3R agonist probe.
- Selective agonists and antagonists separate MC3R from MC4R effects.
- Framing is receptor neurocircuitry research, not human or therapeutic use.
Signal transduction and downstream cascades
Across the subtypes, the proximal event after MT-2 binding is Gs-mediated activation of adenylyl cyclase and a rise in intracellular cAMP, the canonical second messenger for the family. cAMP activates protein kinase A, which phosphorylates transcription factors including CREB; in pigment cells this converges on the MITF program described above, while in central neurons it modulates the excitability and gene expression of melanocortin-responsive circuits. Functional assays commonly quantify this axis directly by measuring cAMP accumulation or CREB phosphorylation in receptor-expressing cells.
As with many GPCRs, melanocortin receptors also recruit beta-arrestins and can signal through MAPK/ERK cascades, and there is research interest in biased agonism and in receptor internalization and desensitization following sustained agonist exposure. A long-acting agonist such as MT-2 is a useful reagent for studying these trafficking and desensitization dynamics because its stability allows prolonged, well-defined receptor occupancy in an assay. These are mechanistic questions about GPCR pharmacology addressed in controlled in-vitro systems.
- Primary pathway: Gs to adenylyl cyclase to cAMP to PKA to CREB.
- MC1R output converges on the MITF pigmentation program.
- Beta-arrestin recruitment and ERK signaling are also studied.
- MT-2 stability aids study of receptor internalization and desensitization.
MT-2 as a research reference compound
Taken together, the properties above explain why MT-2 occupies a specific niche in melanocortin research: it is a conformationally constrained, metabolically stable, broadly active agonist that reliably drives the cAMP axis across four of the five receptor subtypes. That combination makes it a convenient positive-control and pathway-activating reagent, provided its non-selectivity is controlled for with orthogonal selective ligands and genetic tools. Its published molecular identifiers allow each lot to be confirmed for identity before use.
Kairo Labs supplies Melanotan II as a reference material for in-vitro and preclinical research use only. It is not a drug, cosmetic, dietary supplement, or medical product, and it is not intended for human or animal administration; no tanning, cosmetic, appetite, or other physiological benefit is claimed or implied. Laboratories should confirm identity and purity against a lot-specific certificate of analysis and follow standard reconstitution and cold-chain storage practice for a lyophilized cyclic peptide.
- Value as a broad, stable melanocortin agonist positive control.
- Non-selectivity must be controlled with selective ligands and knockouts.
- Confirm each lot against a certificate of analysis before use.
- Reference material for in-vitro/preclinical research use only.